AUSTRALIAN BREAST CANCER PATIENTS ENROLLED IN THE LAPATINIB EXPANDED ACCESS PROGRAM (LEAP)

被引：0
|
作者：
Lynch, J. [1 ,2 ]
Boyle, F. [3 ]
Wilkin, N. [4 ]
Hague, C. [5 ]
机构：
[1] St George Hosp, Canc Serv, Kogarah, NSW, Australia
[2] Sutherland Hosp, Canc Serv, Kogarah, NSW, Australia
[3] Mater Hosp, Sydney, NSW, Australia
[4] Westmead Hosp, Westmead, NSW 2145, Australia
[5] Sutherland Hosp, Caringbah, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety Data of Taiwan Breast Cancer Patients Enrolled in the Lapatinib Expanded Access Program (LEAP)
    Chen, S-C
    Huang, C-S
    Tsao, C-J
    Liu, M-C
    Yeh, D-C
    Hou, M-F
    Chang, T-W
    Hsien, R-K
    Chao, T-Y
    Tai, C-J
    Lin, Y-C
    CANCER RESEARCH, 2009, 69 (24) : 796S - 796S
  • [2] Taiwanese patients with breast cancer with brain metastasis (BM) enrolled in the Lapatinib Expanded Access Program (LEAP).
    Huang, C.
    Chen, S.
    Liu, M.
    Yeh, D.
    Hou, M.
    Chang, T.
    Hsieh, R. K.
    Chao, T.
    Tai, C. J.
    Tsao, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] LAPATINIB EXPANDED ACCESS PROGRAM (LEAP): UPDATED SAFETY DATA
    de Placido, S.
    Capri, G.
    Ro, J.
    Danese, S.
    Chen, S.
    Byrne, J.
    Rosenlund, J.
    Gress, M.
    Oliva, C.
    Parikh, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 66 - 66
  • [4] Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)
    Boccardo, F.
    Kaufman, B.
    Baselga, J.
    Dieras, V.
    Link, J.
    Casey, M. A.
    Fittipaldo, A.
    Oliva, C.
    Zembryki, D.
    Rubin, S. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Lapatinib Expanded Access Program (LEAP): design, operation and initial safety data.
    De, Placido S.
    Link, J.
    Conte, P. F.
    Capri, G.
    Kaufmann, B.
    Byrne, J.
    Rosenlund, J.
    Gress, M.
    Zembryki, D.
    Oliva, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S273 - S273
  • [6] LAPATINIB AS SALVAGE THERAPY IN METASTATIC BREAST CANCER: RESULTS FROM AN EXPANDED ACCESS PROGRAM
    Giotta, F.
    Latorre, A.
    Oliva, S.
    Delcuratolo, S.
    Cramarossa, A.
    D'Amico, C.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 63 - 64
  • [7] Lapatinib as salvage therapy in metastatic breast cancer: Preliminary results from an expanded access program
    Giotta, F.
    Latorre, A.
    Monticelli, G.
    Oliva, S.
    Albano, D.
    Colucci, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Combination Therapy of Lapatinib and Capecitabine for ErbB2-Positive Metastatic or Locally Advanced Breast Cancer: Results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe
    Greil, Richard
    Borstnar, Simona
    Petrakova, Katarina
    Marcou, Yiola
    Pikiel, Joanna
    Wojtukiewicz, Marek Z.
    Koza, Ivan
    Steger, Guenther G.
    Linn, Meinolf
    Das Gupta, Ash
    Cwiertka, Karel
    ONKOLOGIE, 2011, 34 (05): : 233 - 238
  • [9] Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)
    Lin, M. M.
    Pan, X.
    Hou, P.
    Allen, S.
    Baumann, P.
    Hochmair, M. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 42 - 42
  • [10] A single-institution experience from the Lapatinib Expanded Access Program - effect of lapatinib and capecitabine combination therapy on CNS metastases in patients with ErbB2+metastatic breast cancer
    Kaufman, B.
    Weitzen, R.
    Goldfarb, A.
    Ephrat, N.
    Kuchuk, I.
    Golan, T.
    Wolf, I.
    Elia, R.
    EJC SUPPLEMENTS, 2008, 6 (07): : 175 - 175
12345